1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Supports pilot and feasibility studies (using an R34 mechanism) to develop and test interventions or service research frameworks addressing substance use and HIV prevention.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
Opportunity Listing - Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) Simpler. Grants. gov uses Login.
gov to verify your identity and manage your account securely. You don't need a separate username or password for this site. Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93.
310 -- Trans-NIH Research Support 93. 681 -- Office of Disease Prevention 93. 279 -- Drug Use and Addiction Research Programs Last Updated: October 19, 2026 View version history on Grants.
gov The purpose of this notice of funding opportunity (NOFO) is to support pilot and feasibility studies to inform the design and conduct of efficacy, effectiveness, and/or services research trials.
Topics may include: 1) developing interventions to prevent substance use, misuse, or progression to substance use disorder; 2) prevention, treatment, or recovery services research, including research addressing comorbid pain and medical and mental health disorders; and 3) HIV eradication research, including implementation science, prevention, treatment and recovery in substance use settings/populations.
For-profit organizations other than small businesses Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Public and state institutions of higher education Independent school districts Private institutions of higher education Special district governments Federally recognized Native American tribal governments City or township governments Public and Indian housing authorities Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations.
See NIH Grants Policy Statement 16. 8 Collaborative International Research Awards. Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding.
This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors. Grantor contact information pilotstudies@mail. nih.
gov pilotstudies@mail. nih. gov pilotstudies@mail.
nih. gov File name Description Last updated PAR-28-093-Full-Announcement. html PAR-28-093-Full-Announcement.
html Oct 19, 2026 12:01 PM UTC Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Independent researchers and investigators affiliated with domestic public/private non-profit or for-profit institutions. Confirm the full requirements in the official notice before applying.
Applications for Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) are due July 17, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) is funded by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIDA SBIR/STTR Programs (Digital Health Technologies to Address the Social Determinants of Health in context of SUDs) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). NIDA's SBIR/STTR programs have a specific interest in digital health technologies to address social determinants of health in the context of Substance Use Disorders (SUDs). This includes developing innovative technologies targeting SUDs, which aligns with behavioral health technology app innovation.
Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). This funding opportunity invites applications addressing urgent research needs in substance use epidemiology and health services, including pilot studies on emerging drug issues, unexpected prescription drug abuse trends, and timely medical system challenges.
NIDA Core "Center of Transformative Science" Grant Program is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). NIDA supports Core Centers of Transformative Science Grants to bring together investigators funded by NIH or other sources to enhance research relevant to substance use, addiction, and HIV.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNICHD forecast RFA-HD-28-005 (CAPSTONE), RFA-HD-28-006 (Learning Disabilities Research Centers), and RFA-HD-28-001 (Discovery Gateway) on October 20, 2026. All three are due around October 1, 2027. Here is what the incumbents hold and how challengers should prepare.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read article